These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27207972)

  • 1. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.
    Chao TH; Chen IC; Li YH; Lee PT; Tseng SY
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
    Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.
    Chen IC; Tseng WK; Li YH; Tseng SY; Liu PY; Chao TH
    Oncotarget; 2017 Dec; 8(64):108042-108053. PubMed ID: 29296222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V
    Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.
    Furuhashi M; Omori A; Matsumoto M; Kataoka Y; Tanaka M; Moniwa N; Ohnishi H; Yoshida H; Saitoh S; Shimamoto K; Miura T
    Am J Cardiol; 2016 Jul; 118(2):198-203. PubMed ID: 27241838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
    Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
    Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
    Pott J; Schlegel V; Teren A; Horn K; Kirsten H; Bluecher C; Kratzsch J; Loeffler M; Thiery J; Burkhardt R; Scholz M
    Circ Genom Precis Med; 2018 May; 11(5):e001992. PubMed ID: 29748315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.
    Dalgic Y; Abaci O; Kocas C; Cetinkal G; Dalgic SN; Buyuk A; Ser OS; Batit S; Arat A; Gurmen AT
    Coron Artery Dis; 2020 Jan; 31(1):81-86. PubMed ID: 31206403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
    Feder S; Wiest R; Weiss TS; Aslanidis C; Schacherer D; Krautbauer S; Liebisch G; Buechler C
    Lipids Health Dis; 2021 Jan; 20(1):6. PubMed ID: 33461570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study.
    Kheirkhah A; Lamina C; Rantner B; Kollerits B; Stadler M; Pohlhammer J; Klein-Weigel P; Fraedrich G; Kronenberg F
    Atherosclerosis; 2021 Jan; 316():41-47. PubMed ID: 33302043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
    Liu A; Rahman M; Hafström I; Ajeganova S; Frostegård J
    Lupus; 2020 Jul; 29(8):825-835. PubMed ID: 32479241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
    Ruscica M; Ferri N; Fogacci F; Rosticci M; Botta M; Marchiano S; Magni P; D'Addato S; Giovannini M; Borghi C; Cicero AFG;
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28468788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients.
    Blanchard C; Ledoux S; Verhaegen A; Wargny M; Letessier E; Stepanian A; Huten N; Jacobi D; Krempf M; Le Bras M; Perrocheau Guillouche M; Arnaud L; Pichelin M; Van Gaal L; Cariou B; Le May C
    Diabetes Metab; 2020 Nov; 46(6):480-487. PubMed ID: 32032671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.